金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01548 金斯瑞生物科技

已收盘 06-26 16:08:11

11.790

-0.240

-2.00%

最高12.530	最低11.700	成交量1,274万
今开11.790	昨收12.030	日振幅6.90%
总市值257.97亿	流通市值257.97亿	总股本21.88亿
成交额1.52亿	换手率0.58%	流通股本21.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":11.79,"timestamp":1782461291004,"preClose":12.03,"halted":0,"volume":12740422,"delay":0,"changeRate":-0.019950124688279322,"floatShares":2188000000,"shares":2188000000,"eps":-1.927586125771466,"marketStatus":"已收盘","change":-0.24,"latestTime":"06-26 16:08:11","open":11.79,"high":12.53,"low":11.7,"amount":152288301,"amplitude":0.068994,"askPrice":11.79,"askSize":4000,"bidPrice":11.75,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-1.9279547040786722,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":5,"adr":0,"listingDate":1451404800000,"exchange":"SEHK","adjPreClose":12.03,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":0.461915,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548/wiki","defaultTab":"wiki","newsList":[{"id":"2645866019","title":"CXO概念走强 凯莱英 (06821) 涨 17.77% BIO2026大会看好中国CXO高效率优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2645866019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645866019?lang=zh_cn&edition=full","pubTime":"2026-06-24 11:17","pubTimestamp":1782271026,"startTime":"0","endTime":"0","summary":"全球生物技术领域盛会BIO2026大会于6月22日至25日在美国圣地亚哥召开，汇聚全球超20000名行业参与者，覆盖人工智能与数字健康、细胞与基因治疗等前沿领域，中国CXO企业的高效率优势备受关注。光大证券研报指，2026年6月22日至25日BIO2026大会举办，70余个国家超2万名业内人士参会，覆盖18大生物医药核心议题，凯莱英、泰格医药、博腾股份等国内CXO企业参展，英硅智能同期落地AI药物研发海外合作。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","01548","BK1141","LU0140636845.USD","06127","LU0572944931.SGD","LU1046422090.SGD","LU0588546209.SGD","002821","BK1521","LU0326950275.SGD","LU0516422952.EUR","03759","LU0456846285.SGD","LU0320764599.SGD","LU0348766576.USD","06821","LU0819121731.USD","03347","HK0000306685.HKD","LU1880383366.USD","LU2242644610.SGD","LU0708995583.HKD","SG9999002463.SGD","LU0359202008.SGD","HK0000320264.USD","LU0052750758.USD","LU1794554557.SGD","LU1720050803.USD","LU3063872942.SGD","LU0359201612.USD","BK0239","LU0856984785.SGD","LU0327786744.USD","BK1583","CXO","LU0043850808.USD","BK0132","HK0000320223.HKD","LU1328615791.USD","HK0000306701.USD","LU1242518931.SGD","LU0039217434.USD","LU0456827905.SGD","LU0516422366.SGD","LU2039709279.SGD","LU0348735423.USD","BK1576","02269","LU0051755006.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645865054","title":"CRO概念股早盘表现强势 凯莱英涨超14%金斯瑞生物科技涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645865054","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645865054?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:35","pubTimestamp":1782268500,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　CRO概念股早盘表现强势，截至发稿，凯莱英（06821）上涨14.05%，报110.40港元；金斯瑞生物科技（01548）上涨8.56%，报11.80港元；药明康德（02359）上涨8.56%，报142港元；泰格医药（03347）上涨5.67%，报32.74港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-24/doc-inienpmx8299253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0132","BK1583","BK1576","HK0000320223.HKD","BK1191","002821","06821","01548","HK0000306701.USD","BK1141","BK0239","LU1328615791.USD","HK0000306685.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645653708","title":"港股异动 | CRO概念股表现强势 BIO大会凸显中国CXO全球竞争力 医药领域开放迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2645653708","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645653708?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:00","pubTimestamp":1782266401,"startTime":"0","endTime":"0","summary":"消息面上，BIO 2026国际生物科技大会于6月22日至25日在美国圣地亚哥召开，中国CXO企业的高效率优势得到全球认可，海外订单拓展空间进一步打开。东方证券发布研报称，从CXO景气度关键指标的最新数据来看：2026年前五个月，国内资金端、研发端、订单端多重因素共振向上，国内CXO行业高景气持续。该行认为，国内CXO公司订单充足、量价双升，随着订单执行转化，将会带来报表端大幅改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1046422090.SGD","BK1576","LU0348766576.USD","03347","HK0000306701.USD","BK1574","LU0052750758.USD","HK0000320223.HKD","06821","BK4585","HK0000320264.USD","159938","CXO","LU1169589451.USD","01548","HK0000306685.HKD","BK1583","LU0708995583.HKD","LU2125910500.SGD","BK1141","BK1161","LU0348767384.USD","BK4121","VXUS","LU0320764599.SGD","LU2242644610.SGD","BIO","BK1515","BK4588","02359","LU1169590202.USD","LU2045819591.USD","09939","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114917963","title":"异动解读｜金斯瑞生物科技盘中上涨5.34%，此前因传奇生物美股大跌回调后呈修复走势","url":"https://stock-news.laohu8.com/highlight/detail?id=1114917963","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114917963?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:41","pubTimestamp":1782265310,"startTime":"0","endTime":"0","summary":"6月24日，金斯瑞生物科技盘中上涨5.34%，报11.58港元，成交额3764.29万港元。消息面上，公司股价此前于6月22日因联营公司传奇生物美股大幅下跌而回调逾8%至10.76港元附近，当前呈现技术性修复走势。同日生命科学板块整体回暖，药明康德涨3.75%、药明生物涨2.63%、药明合联涨5.3%，板块情绪改善对股价形成支撑。金斯瑞生物科技是一家主要从事生命科学研究产品及服务的投资控股公司，旗下细胞疗法分部通过联营公司传奇生物开发CAR-T疗法，主要在中国及海外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167041365","title":"异动解读｜金斯瑞生物科技盘中下跌8.14%，联营公司传奇生物美股大跌拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1167041365","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167041365?lang=zh_cn&edition=full","pubTime":"2026-06-22 10:13","pubTimestamp":1782094439,"startTime":"0","endTime":"0","summary":"6月22日，金斯瑞生物科技盘中下跌8.14%，报10.76港元，成交额1.03亿港元。消息面上，公司联营公司传奇生物上周五在美股大幅下跌，市场情绪传导至港股母公司。同日生命科学板块整体走弱，药明生物跌3.18%、晶泰控股跌3.93%、英矽智能跌2.66%，行业情绪低迷进一步加剧抛压。金斯瑞生物科技是一家主要从事生命科学研究产品及服务的投资控股公司，旗下细胞疗法分部通过联营公司传奇生物开发CAR-T疗法，主要在中国及海外市场开展业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114814294","title":"异动解读｜金斯瑞生物科技盘中上涨5.41%，此前传奇生物LB2501临床数据积极后股价回升","url":"https://stock-news.laohu8.com/highlight/detail?id=1114814294","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114814294?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:28","pubTimestamp":1781749688,"startTime":"0","endTime":"0","summary":"6月18日，金斯瑞生物科技盘中上涨5.41%，报11.88港元，成交额9002.89万港元。此前公司股价因利好兑现一度回调逾9%，当前呈现修复走势。消息面上，公司联营公司传奇生物于6月14日在欧洲血液学协会年会上公布潜在同类首创体内CD19/CD20双靶点CAR-T疗法LB2501的I期临床概念验证数据。同日生命科学板块整体走强，药明生物涨4.62%、英矽智能涨6.18%，板块情绪回暖亦对股价形成支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644314776","title":"创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644314776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644314776?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:21","pubTimestamp":1781749308,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念普涨，截至发稿，再鼎医药 涨6.34%，康方生物涨5.96%，药明康德涨3.59%，康诺亚-B涨3.49%，亚盛医药涨3.45%，药明生物涨3.08%，金斯瑞生物科技涨2.93%，百济神州涨2.60%。华鑫证券研究称，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984066","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303224171.USD","LU0516423091.SGD","01548","LU1969619763.USD","LU0417516571.SGD","LU0307460666.USD","02359","BK4526","BK1583","ZLAB","LU2242644610.SGD","BK1141","BK1161","BK1588","BK4531","LU2488822045.USD","09926","LU0348827113.USD","LU0516423174.USD","SG9999002463.SGD","IE00BPRC5H50.USD","LU0561508036.HKD","02269","LU0140636845.USD","LU0588546209.SGD","LU1720050803.USD","06855","HK0000306701.USD","HK0000320223.HKD","LU2328871848.SGD","LU1961090484.USD","LU0348784397.USD","LU1794554557.SGD","HK0000306685.HKD","BK1521","LU0516422366.SGD","LU2476274308.USD","159992","LU0456846285.SGD","06978","BK1589","06160","LU0326950275.SGD","BK1587","09688","LU1719994722.HKD","LU0516422952.EUR","LU2045819591.USD","LU0979878070.USD","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644307776","title":"医药外包概念回暖 昭衍新药(06127)涨4.47%、药明康德(02359)涨3.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644307776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644307776?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:15","pubTimestamp":1781748909,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念回暖，截至发稿，昭衍新药 涨4.47%，药明康德涨3.35%，药明生物涨2.75%，金斯瑞生物科技涨2.31%，凯莱英涨1.24%，康龙化成涨1.06%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984065","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","02269","03759","LU0588546209.SGD","LU0307460666.USD","LU0572944931.SGD","LU0348735423.USD","BK1574","LU1688375341.USD","LU0979878070.USD","BK1141","LU1046422090.SGD","LU1997245094.SGD","603259","LU0326950275.SGD","IE00BPRC5H50.USD","LU0516422366.SGD","LU1242518931.SGD","LU2495084118.USD","LU2045819591.USD","02359","LU1303224171.USD","159938","06127","LU0327786744.USD","LU0348767384.USD","LU0140636845.USD","LU1979443071.USD","BK1161","LU0359201612.USD","LU0516422440.USD","LU0359202008.SGD","LU1997244956.HKD","SG9999002562.SGD","LU2488822045.USD","01548","SG9999002463.SGD","IE00B0JY6N72.USD","LU0823426480.USD","06821","BK1589","BK1515","LU0516422952.EUR","IE00B543WZ88.USD","09939","LU1251922891.USD","LU0051755006.USD","LU0456846285.SGD","603127","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643522150","title":"港股异动 | 金斯瑞生物科技(01548)一度跌超10% 传奇生物淋巴瘤疗法研究客观缓解率达100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643522150","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643522150?lang=zh_cn&edition=full","pubTime":"2026-06-15 11:20","pubTimestamp":1781493658,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技一度跌超10%，截至发稿，跌8.37%，报11.93港元，成交额2.95亿港元。消息面上，金斯瑞生物科技联营公司传奇生物日前宣布，其针对复发/难治性B细胞非霍奇金淋巴瘤患者的在研体内CD19/CD20双靶点CAR-T细胞疗法LB2501首次临床概念验证数据。在一项正在开展的I期研究中，复发/难治性B细胞非霍奇金淋巴瘤患者接受单次输注后，在第2剂量水平达到了100%的ORR和83.3%的CR率。截至数据截止时，所有缓解仍在持续。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","HK0000306701.USD","BK4505","BK1576","HK0000320264.USD","01548","BK4588","LEGN","BK1141","BK4139","HK0000306685.HKD","BK4585","HK0000320223.HKD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","LU1960683339.HKD","02268","HK0000320264.USD","BK1576","01177","LU0348827113.USD","LU0051755006.USD","09966","01093","LU2097828631.EUR","01801","01530","LU0320764599.SGD","06990","09926","LU0456827905.SGD","LU0502904849.HKD","06996","01952","02269","LU0819121731.USD","03692","03759","06160","LU2399975544.HKD","09996","IE00BZ08YR35.GBP","LU0140636845.USD","03329","06078","01951","LU0737861772.HKD","LU1242518857.USD","02596","SG9999002562.SGD","BK1191","LU1688375341.USD","06821","HK0000306685.HKD","01548","LU1880383366.USD","02096","02273","IE00B0JY6N72.USD","LU0181495838.USD","01276","LU1226287875.USD","02162","LU3063872942.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643495892","title":"金斯瑞生物科技(01548)：传奇潜在“同类首创”体内CD19/CD20双靶点CAR-T疗法LB2501在复发/难治性B细胞非霍奇金淋巴瘤中获得临床概念验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2643495892","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643495892?lang=zh_cn&edition=full","pubTime":"2026-06-14 18:18","pubTimestamp":1781432300,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 发布公告，本公司联营公司传奇生物科技股份有限公司于2026年6月14日发布新闻稿，宣布其针对复发/难治性B细胞非霍奇金淋巴瘤患者的在研体内CD19/CD20双靶点CAR-T细胞疗法LB2501首次临床概念验证数据。在这项正在开展的I期研究中，单次输注LB2501在无需进行淋巴细胞清除的情况下，实现了体内CAR-T细胞的剂量依赖性扩增。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4230","CAR","HK0000320264.USD","BK1141","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","BK4022","BK1576","01548","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173569654","title":"异动解读｜金斯瑞生物科技盘中下跌5.05%，CXO板块持续承压叠加美国对华生物医药投资限制担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1173569654","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173569654?lang=zh_cn&edition=full","pubTime":"2026-06-09 11:05","pubTimestamp":1780974321,"startTime":"0","endTime":"0","summary":"6月9日，金斯瑞生物科技盘中下跌5.05%，报11.46港元/股，成交额9887.48万港元。消息面上，医药外包（CXO）概念股近日持续全线走弱，板块联动效应显著。此前一个交易日，药明生物跌超7%、药明合联跌超6%、康龙化成跌超6%，行业集体承压。与此同时，市场对美国拟限制甚至禁止对中国新药研发投资的政策担忧再度升温，进一步压制生物医药板块风险偏好。金斯瑞生物科技近期虽在股东大会上释放盈利改善及资本回报预期，但政策面不确定性与板块系统性抛压仍主导短期走势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182809006","title":"异动解读｜金斯瑞生物科技盘中下跌7.04%，医药外包概念股全线走弱板块承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1182809006","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182809006?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:01","pubTimestamp":1780902115,"startTime":"0","endTime":"0","summary":"6月8日，金斯瑞生物科技盘中下跌7.04%，报12.01港元/股，成交额1.55亿港元。消息面上，当日医药外包概念股全线走低，CXO板块集体承压。药明生物跌超7%、方达控股跌逾7%、药明合联跌超6%，板块联动效应显著加剧个股下行压力。港股大盘同步走弱，恒生科技指数下跌2.4%，市场风险偏好明显回落。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641105779","title":"医药外包概念股全线走低 金斯瑞生物科技(01548)跌7.43%、药明生物(02269)跌7.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2641105779","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641105779?lang=zh_cn&edition=full","pubTime":"2026-06-08 13:43","pubTimestamp":1780897412,"startTime":"0","endTime":"0","summary":"中邮证券表示，2026年第一季度，海外CXO行业整体呈现分化复苏格局，全球生物制药融资环境出现实质性改善，带动需求逐步回暖，但早期初创企业资金压力仍未完全缓解，不同细分赛道、不同规模企业的表现存在差异，行业结构性分化特征进一步凸显。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983281","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880383366.USD","LU0320764599.SGD","LU0516422952.EUR","BK1515","LU0348766576.USD","LU3063872942.SGD","06127","LU1046422090.SGD","LU0708995583.HKD","LU2039709279.SGD","LU1720050803.USD","BK1521","LU0588546209.SGD","SG9999002463.SGD","01873","LU2242644610.SGD","03347","LU0516423091.SGD","09939","LU0856984785.SGD","LU0417516902.SGD","LU0516422366.SGD","BK1191","LU0039217434.USD","LU0572944931.SGD","LU0417516738.SGD","LU0326950275.SGD","LU2045819591.USD","02359","HK0000306685.HKD","159938","LU0140636845.USD","LU0051755006.USD","03759","LU0307460666.USD","BK1589","BK1141","LU0348767384.USD","02269","LU1688375341.USD","LU0359201612.USD","01521","LU0348735423.USD","LU0456827905.SGD","01548","BK1574","06821","HK0000320264.USD","HK0000320223.HKD","LU0516422440.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165362","title":"金斯瑞生物科技(01548)授出合共1473.67万个限制性股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165362","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640165362?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:42","pubTimestamp":1780584169,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，于2026年6月4日，本公司向4名董事、本公司轮值首席执行官、若干雇员及一名服务提供者授出合共1473.67万个限制性股份单位，惟待接纳及须遵守2021年限制性股份单位计划的条款及条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","HK0000306701.USD","BK1141","HK0000306685.HKD","HK0000320223.HKD","BK1576","01548","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640972760","title":"港股收盘(06.03) | 恒指收跌1.56% 光通信概念逆市走强 油气股午后拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=2640972760","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640972760?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:22","pubTimestamp":1780474925,"startTime":"0","endTime":"0","summary":"截至收盘，恒生指数跌1.56%或405.11点，报25633.21点，全日成交额3229.21亿港元；恒生国企指数跌1.9%，报8596.59点；恒生科技指数跌2.74%，报5056.97点。截至收盘，跌3.16%，报466.4港元，成交额229.95亿港元，拖累恒指61.39点。隔夜美股市场光通信龙头迈威尔科技股价大涨超30%。截至收盘，跌10.25%，报17.95港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","01888","MCHmain","02833","BK1576","LU2929501877.USD","HK0000320223.HKD","SG9999006597.SGD","03037","BK1170","HK0000306701.USD","00568","BK1240","01548","LU0307460666.USD","83115","07200","HHImain","BK4588","LU0314109678.HKD","LU2039709279.SGD","06869","HK0000306685.HKD","02800","159195","BK1583","VXUS","513600","BK1506","BK1523","LU1328277881.USD","82800","03419","MHImain","HSImain","BK1141","LU2187417386.USD","HK0000320264.USD","BK1149","02553","LU2351347302.SGD","BK4585","06166","07500","BK1202","HSI","07300","LU1813983027.USD","09115","03115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640927867","title":"港股异动 | 金斯瑞生物科技(01548)高开近15% 传奇生物披露治疗淋巴瘤初步临床数据显示积极信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2640927867","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640927867?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:23","pubTimestamp":1780449806,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技高开近15%，截至发稿，涨14.99%，报13.96港元，成交额617.03万港元。6月2日晚，金斯瑞生物科技公布，美国上市联营公司传奇生物披露在研体内CD19/CD20双靶点CAR-T细胞疗法LB2501在复发或难治性B细胞非霍奇金淋巴瘤患者中的初步临床数据。通过在患者体内直接生成CAR-T细胞，该方法有望简化治疗流程，并提升传统CAR-T细胞疗法难以覆盖患者的可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","01548","HK0000306685.HKD","HK0000306701.USD","HK0000320264.USD","BK1583","LEGN","HK0000320223.HKD","BK4505","VXUS","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147210091","title":"金斯瑞生物科技更新5月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1147210091","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147210091?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:12","pubTimestamp":1780387937,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技股份有限公司于2026年6月2日发布截至2026年5月31日的股份变动月报表。公告显示，公司法定股本维持为50亿美元，与上月保持一致。公司确认已满足香港联交所对公众持股比例的相关要求。报告期内未出现注銷或库藏股变动，总股本相较上月小幅增长，库存股份数目为零。公司表示将持续遵守香港联交所《上市规则》及相关法律法规，保持规范运作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968362","title":"金斯瑞生物科技(01548)：传奇于2026年ASCO大会公布LB2102治疗实体瘤的首次人体研究结果及CARVYKTI®治疗多发性骨髓瘤的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968362","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640968362?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:52","pubTimestamp":1780325527,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，公司联营公司传奇生物科技股份有限公司(“传奇”，其股份以美国存托股份形式于美国纳斯达克全球精选市场上市)于2026年6月1日(纽约时间)(2026年6月1日香港交易时段后)已向美国证券交易委员会提交6-K表格，并发布新闻稿公布其靶向DLL3的在研CAR-T细胞疗法LB2102在复发或难治性小细胞肺癌(SCLC)或大细胞神经内分泌癌(LCNEC)患者中的首次人体试验数据，同时亦公布了来自 CARTITUDE 项目的最新分析 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金斯瑞生物科技(01548)：传奇于2026年ASCO大会公布LB2102治疗实体瘤的首次人体研究结果及CARVYKTI®治疗多发性骨髓瘤的最新数据","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","BK1583","HK0000320223.HKD","BK1141","BK1576","HK0000320264.USD","HK0000306701.USD","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179476257","title":"异动解读 | 金斯瑞生物科技盘中大跌5.26%，ASCO利好消化叠加板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1179476257","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179476257?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:08","pubTimestamp":1780283329,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技今日盘中出现大幅下跌，跌幅达5.26%，引发市场关注。消息面上，公司联营公司传奇生物此前在ASCO年会上发布了多项研究成果，包括靶向DLL3的CAR-T疗法LB2102的临床数据及CARVYKTI新数据。这一利好消息曾在之前推动股价显著上涨，目前市场正处于对该利好的持续消化阶段，部分投资者选择获利了结。此外，港股通资金此前连续出现大额净流出，机构借利好减持的行为也引发了市场的警惕。从行业层面看，今日生命科学工具和服务板块整体表现疲软，多只相关个股下跌，板块的联动效应进一步加剧了金斯瑞生物科技的下行压力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genscript.com","stockEarnings":[{"period":"1week","weight":0.0204},{"period":"1month","weight":-0.0941},{"period":"3month","weight":0.0838},{"period":"6month","weight":-0.0782},{"period":"1year","weight":-0.1959},{"period":"ytd","weight":-0.0314}],"compareEarnings":[{"period":"1week","weight":-0.0354},{"period":"1month","weight":-0.0985},{"period":"3month","weight":-0.0751},{"period":"6month","weight":-0.1062},{"period":"1year","weight":-0.0571},{"period":"ytd","weight":-0.0996}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务，旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株，提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.000341},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075475},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.060575},{"month":4,"riseRate":0.545455,"avgChangeRate":0.057883},{"month":5,"riseRate":0.454545,"avgChangeRate":0.061694},{"month":6,"riseRate":0.545455,"avgChangeRate":0.029548},{"month":7,"riseRate":0.6,"avgChangeRate":0.075818},{"month":8,"riseRate":0.4,"avgChangeRate":0.101263},{"month":9,"riseRate":0.4,"avgChangeRate":-0.071937},{"month":10,"riseRate":0.6,"avgChangeRate":0.095918},{"month":11,"riseRate":0.6,"avgChangeRate":0.045101},{"month":12,"riseRate":0.3,"avgChangeRate":0.042047}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}